Neuroleptic malignant syndrome

Am J Psychiatry. 2007 Jun;164(6):870-6. doi: 10.1176/ajp.2007.164.6.870.
No abstract available

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Amantadine
  • Antiparkinson Agents / therapeutic use
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use
  • Benzodiazepines / therapeutic use
  • Bromocriptine / therapeutic use
  • Dantrolene / therapeutic use
  • Diagnosis, Differential
  • Dopamine / physiology
  • Electroconvulsive Therapy
  • Female
  • Humans
  • Lorazepam / therapeutic use
  • Muscle Relaxants, Central / therapeutic use
  • Neuroleptic Malignant Syndrome / diagnosis*
  • Neuroleptic Malignant Syndrome / drug therapy
  • Neuroleptic Malignant Syndrome / physiopathology
  • Risk Factors

Substances

  • Antiparkinson Agents
  • Antipsychotic Agents
  • Muscle Relaxants, Central
  • Benzodiazepines
  • Bromocriptine
  • Amantadine
  • Dantrolene
  • Lorazepam
  • Dopamine